

Eric Plitman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6120802/publications.pdf>

Version: 2024-02-01

58
papers

1,642
citations

304743

22
h-index

330143

37
g-index

60
all docs

60
docs citations

60
times ranked

2727
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 744-757.	7.9	60
2	Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation study. <i>Schizophrenia Research</i> , 2022, 243, 268-275.	2.0	22
3	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E1-E10.	2.4	12
4	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
5	Benzodiazepine Sedation and Postoperative Neurological Deficits after Awake Craniotomy for Brain Tumor – An Exploratory Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 885164.	2.8	2
6	Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab006.	1.7	14
7	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. <i>JAMA Psychiatry</i> , 2021, 78, 667.	11.0	72
8	Hippocampal subfield volumes across the healthy lifespan and the effects of MR sequence on estimates. <i>NeuroImage</i> , 2021, 233, 117931.	4.2	19
9	The impact of the Siemens Tim Trio to Prisma upgrade and the addition of volumetric navigators on cortical thickness, structure volume, and 1H-MRS indices: An MRI reliability study with implications for longitudinal study designs. <i>NeuroImage</i> , 2021, 238, 118172.	4.2	7
10	Hippocampal shape across the healthy lifespan and its relationship with cognition. <i>Neurobiology of Aging</i> , 2021, 106, 153-168.	3.1	22
11	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102852.	2.7	9
12	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , 2020, 45, 632-640.	5.4	50
13	Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109839.	4.8	16
14	Volumetric, shape and microstructural alterations of the hippocampal subfields in healthy aging. <i>Alzheimer's and Dementia</i> , 2020, 16, e039589.	0.8	1
15	Seeing the bigger picture: multimodal neuroimaging to investigate neuropsychiatric illnesses. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 147-149.	2.4	5
16	Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. <i>Journal of Psychiatric Research</i> , 2020, 124, 151-158.	3.1	31
17	DAS: The Diabetes Awareness and Insight Scale. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 189-194.	3.6	7
18	White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109871.	4.8	21

#	ARTICLE	IF	CITATIONS
19	Frontostriatal Structural Connectivity and Striatal Glutamatergic Levels in Treatment-Resistant Schizophrenia: An Integrative Analysis of DTI and 1H-MRS. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
20	Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2019, 210, 13-20.	2.0	5
21	Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. <i>European Psychiatry</i> , 2019, 61, 63-71.	0.2	12
22	Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2019, 211, 10-20.	2.0	15
23	The role of maternal immune activation in altering the neurodevelopmental trajectories of offspring: A translational review of neuroimaging studies with implications for autism spectrum disorder and schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 104, 141-157.	6.1	54
24	Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 208, 420-429.	2.0	32
25	Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2019, 33, 1199-1214.	4.0	47
26	Subiculum volumes associated with memory function in the oldest-old individuals aged 95+ years and older. <i>Geriatrics and Gerontology International</i> , 2019, 19, 347-351.	1.5	5
27	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5
28	A meta-analysis of transcranial direct current stimulation for schizophrenia: "œels more better?â€ <i>Journal of Psychiatric Research</i> , 2019, 110, 117-126.	3.1	40
29	Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, 596-605.	1.3	94
30	Neuroimaging correlates of narcolepsy with cataplexy: A systematic review. <i>Neuroscience Research</i> , 2019, 142, 16-29.	1.9	22
31	Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study. <i>Schizophrenia Research</i> , 2019, 214, 3-10.	2.0	53
32	Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. <i>Psychiatry Research - Neuroimaging</i> , 2018, 273, 16-24.	1.8	14
33	Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. <i>European Neuropsychopharmacology</i> , 2018, 28, 285-296.	0.7	6
34	Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 340-352.	4.8	49
35	Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 523-530.	2.7	11
36	Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. <i>PLoS ONE</i> , 2018, 13, e0209584.	2.5	7

#	ARTICLE	IF	CITATIONS
37	The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. <i>Psychiatry Research</i> , 2018, 268, 114-122.	3.3	62
38	Reprint of OASIS " Obesity Awareness and Insight Scale. <i>Primary Care Diabetes</i> , 2018, 12, 371-378.	1.8	2
39	Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit " Posterior parietal hemispheric imbalance. <i>Medical Hypotheses</i> , 2017, 100, 19-22.	1.5	1
40	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 747-762.	2.6	9
41	The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 341-347.	2.6	4
42	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans. <i>European Neuropsychopharmacology</i> , 2016, 26, 644-652.	0.7	23
43	Benzodiazepine Use Attenuates Cortical β -Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1028-1039.	1.2	19
44	β -Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 923-939.	1.2	15
45	Relapse of ileus in patients with psychiatric disorders: A 2-year chart review. <i>General Hospital Psychiatry</i> , 2016, 38, 31-36.	2.4	1
46	Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 149-159.	2.3	38
47	Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. <i>Schizophrenia Bulletin</i> , 2016, 42, 415-424.	4.3	80
48	The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 49-53.	4.8	17
49	Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 743-754.	2.6	33
50	Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv014-pyv014.	2.1	59
51	Lifetime History of Depression Predicts Increased Amyloid- β Accumulation in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 907-919.	2.6	49
52	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	2.0	22
53	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia " A [11C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	2.0	17
54	Neuroimaging findings in treatment-resistant schizophrenia: A systematic review. <i>Schizophrenia Research</i> , 2015, 164, 164-175.	2.0	75

#	ARTICLE	IF	CITATIONS
55	Non-Pharmacological Management for Patients with Frontotemporal Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2015, 45, 283-293.	2.6	26
56	Dopamine D2/3Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin, 2015, 42, sbv106.	4.3	16
57	Glutamate-mediated excitotoxicity in schizophrenia: A review. European Neuropsychopharmacology, 2014, 24, 1591-1605.	0.7	115
58	Psychosis in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2014, 42, 485-499.	2.6	66